Uptake and safety of Sotrovimab for prevention of severe COVID-19 in a cohort and self-controlled case series study
We find no safety signals of concern for possible adverse outcomes in the period 2-28 days post treatment with Sotrovimab. However, there is evidence of unequal uptake of Sotrovimab treatment across ethnic groups.
Authors
- Julia Hippisley–Cox (ORCID: https://orcid.org/0000-0002-2479-7283)
- Holly Tibble (ORCID: https://orcid.org/0000-0001-7169-4087)
- Andrew JHL Snelling (ORCID: https://orcid.org/0000-0002-2882-2079)
- Aziz Sheikh (ORCID: https://orcid.org/0000-0001-7022-3056)
- Martina Patone (ORCID: https://orcid.org/0000-0001-5954-1045)
- Carol Coupland (ORCID: https://orcid.org/0000-0002-2327-3306)
Institutions
- University of Nottingham (GB)
- University of Oxford (GB)
- University of Edinburgh (GB)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1038/s43856-024-00720-7
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Health Technology Assessment Programme